ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 872,99
0,17%
DAX
18 726,76
-0,21%
Brent Oil
82,275
-0,21%
Bitcoin
70 201,71
0,10%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cyclacel Pharmaceuticals Inc (CYCCP)

  7. Cyclacel Pharmaceuticals Inc (CYCCP) Actualités

CYCCP Cyclacel Pharmaceuticals Inc

6,99
0,00 (0,00%)
21 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Cyclacel Pharmaceuticals Inc CYCCP NASDAQ Action préférentielle
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 6,99 23:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
6,50 6,32 6,50 6,99 6,99
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
17/5/202415:56EDGAR2Form D - Notice of Exempt Offering of Securities
14/5/202423:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202422:05EDGAR2Form 8-K - Current report
14/5/202422:05GLOBECyclacel Pharmaceuticals Reports First Quarter Financial..
13/5/202422:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/5/202415:15GLOBECyclacel Pharmaceuticals to Release First Quarter 2024..
08/5/202403:53EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
08/5/202403:52EDGAR2Form DEF 14A - Other definitive proxy statements
06/5/202423:26EDGAR2Form S-1 - General form for registration of securities under..
02/5/202422:30GLOBECyclacel Pharmaceuticals Announces Closing of $8.0 Million..
30/4/202419:51APS$8 Million Private Placement Announcement Sends Biotech..
30/4/202413:00GLOBECyclacel Pharmaceuticals Announces $8.0 Million Private..
01/4/202415:15GLOBECyclacel Pharmaceuticals to Present New Clinical Data at..
19/3/202421:05GLOBECyclacel Pharmaceuticals Reports Fourth Quarter and Full..
13/3/202421:05GLOBECyclacel Pharmaceuticals to Release Fourth Quarter and Full..
07/3/202415:15GLOBECyclacel Pharmaceuticals Announces Preclinical..
06/3/202415:15GLOBECyclacel Pharmaceuticals Announces Receipt of $2.9 Million..
20/2/202415:15GLOBECyclacel Pharmaceuticals to Participate in 2024 BIO CEO &..
14/2/202422:31EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/2/202416:09EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202421:47EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202423:03EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202422:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202415:15EDGAR2Form 8-K - Current report
30/1/202415:15GLOBECyclacel Pharmaceuticals Announces the Appointment of Brian..
19/1/202422:58EDGAR2Form S-1 - General form for registration of securities under..
12/1/202422:05EDGAR2Form 8-K - Current report
10/1/202419:35EDGAR2Form SC 13G - Statement of acquisition of beneficial..
04/1/202422:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
04/1/202422:05EDGAR2Form 8-K - Current report
26/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/12/202315:29EDGAR2Form 8-K - Current report
26/12/202315:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/12/202315:00GLOBECyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data..
12/12/202322:06EDGAR2Form 8-K - Current report
12/12/202322:05GLOBECyclacel Pharmaceuticals Announces Reverse Stock Split
30/11/202315:15GLOBECyclacel Regains Compliance With Nasdaq Listing Rule..
29/11/202303:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
29/11/202303:20EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
28/11/202323:15GLOBECyclacel Receives Notification of Deficiency From Nasdaq..
28/11/202322:59EDGAR2Form 8-K - Current report
15/11/202323:04EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
15/11/202323:03EDGAR2Form 8-K - Current report
13/11/202322:06EDGAR2Form 8-K - Current report
07/11/202322:10EDGAR2Form 8-K - Current report
07/11/202315:15GLOBECyclacel Pharmaceuticals to Release Third Quarter 2023..
02/11/202321:30EDGAR2Form PRE 14A - Other preliminary proxy statements
08/9/202322:10EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
CYCCP
Cyclacel Pharmaceuticals
NYSE
AMRX
Amneal Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés